Skip to main content
  • ESC: 6-Month DAPT Non-Inferior to Longer Tx Strategy But problems with NIPPON trial highlight challenges of dual antiplatelet therapy research

    ROME — A 6-month regimen of dual antiplatelet therapy (DAPT) with clopidogrel was non-inferior to the practice of 18-month inhibition after stenting with a newer-generation drug-eluting device, the NIPPON study suggested.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details